Manifestations of cardiovascular toxicity associated with the approved tyrosine kinase inhibitors

14152 Background: Since 2001, 5 tyrosine kinase inhibitors (TKi’s; imatinib, erlotinib, sorafenib, sunitinib and dasatinib) have been approved for hematologic and solid tumor indications including,...